PT  - JOURNAL ARTICLE
AU  - H. K. Poulsen
AU  - M. Jacobsen
AU  - K. Bertelsen
AU  - J. E. Andersen
AU  - S. Ahrons
AU  - J. Bock
AU  - E. Bostofte
AU  - S. A. Engelholm
AU  - B. Hølund
AU  - A. Jakobsen
AU  - H. Kiaer
AU  - M. Nyland
AU  - P. H. Pedersen
AU  - I. Strøyer
TI  - Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low-risk cases
AID  - 10.1136/ijgc-00009577-199601000-00006
DP  - 1996 Jan 01
TA  - International Journal of Gynecologic Cancer
PG  - 38--43
VI  - 6
IP  - 1
4099  - http://ijgc.bmj.com/content/6/1/38.short
4100  - http://ijgc.bmj.com/content/6/1/38.full
SO  - Int J Gynecol Cancer1996 Jan 01; 6
AB  - In an attempt to create uniform nationwide guidelines for the management of all stages of endometrial carcinoma, and to limit the use of adjuvant radiation therapy in stage I disease to high-risk patients only, a protocol was developed by the Danish Endometrial Cancer group (DEMCA). From September 1986 through August 1988, 1214 women in Denmark with newly diagnosed carcinoma of the endometrium have been treated according to this protocol. This figure represents all endometrial carcinomas diagnosed in Denmark during this 2-year period. The primary treatment was total abdominal hysterectomy and bilateral salpingo-oophorectomy and no preoperative radiation therapy was delivered. In 1039 cases no macroscopic residual tumor and/or microscopic tumor tissue in the resection margins was found following surgery. Based on surgery and histopathology, these patients were classified as: P-stage I low-risk (grade 1 & 2 and ≤ 50% myometrial invasion), P-stage I high-risk (grade 1 & 2 and > 50% myometrial invasion, and grade 3), P-stage II and P-stage III (Group 1). Distribution was as follows: P-I low-risk 641 patients, P-I high-risk 235, P-II 105 and P-III (Group 1) 58 patients. No postoperative radiation therapy was given to P-I low-risk cases. P-I high-risk, P-II, and P-III (Group 1) cases received external radiation therapy. Recurrence rate at 68-92 months follow-up was 45/641 (7%) in P-I low-risk, 36/235 (15%) in P-I high-risk, 30/105 (29%) in P-II, and 27/58(47%) in P-III (Group 1) cases. Fifteen of 17 vaginal recurrences in P-I low-risk cases were salvaged (mean observation time 61 months).